Speaker Schedule

JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000429221.38888.c2
Speaker Schedule
    Back to Top | Article Outline

    Sunday, October 14, 2012

    Grand Ballroom V

    Track A

    International challenges to HIV Treatment and Prevention: Baltimore to Africa

    Chairs: William Blattner, Institute of Human Virology and John Idoko, National Agency for Control of AIDS

    9:00 Opening Remarks

    9:10 Gumel Aliyu, Institute of Human Virology Nigeria

    Pattern of Mycobacterial Infections and their Associations with HIV among Laboratory Confirmed Cases of Pulmonary Tuberculosis in Nigeria A101

    9:30 John Idoko, National Agency for Control of AIDS

    New Prevention Technologies, what does it mean for Nigeria? A102

    9:50 Chidi Nweneka, African AIDS Vaccine Partnership

    Challenges of staying on the course for a HIV vaccine to end the epidemic in Africa A103

    10:10 Alash’le Abimiku, Institute of Human Virology

    Improving laboratory capacity in Africa through step-wise accreditation program A104

    10:30 Break – 20 minutes

    Chairs: Patrick Dakum, Institute of Human Virology Nigeria and Jeanne McDermott, National Institutes of Health

    10:50 Andrew Kambugu, Makerere University College of Health Sciences

    Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda A105

    11:10 Walter Royal III, University of Maryland School of Medicine

    Neurocognitive Impairment among Treatment-Naïve HIV-Infected Individuals in Nigeria A106

    11:30 Emmanuel A. Abayomi, Tygerberg Hospital, Stellenbosch University

    Lymphoma incidence and HIV-related lymphoma subtypes seen at Tygerberg Academic Hospital, Western Cape, South Africa, 2002-2011 A107

    11:50 Closing remarks - Joseph O’Neill, Director

    Global Health Initiatives, University of Maryland

    12:00 Lunch for Sunday Speakers and Chairs, Grand Ballroom, Salon X

    Track B

    Clinical Science of Antiviral Therapy

    Chairs: John Bartlett, Johns Hopkins University and Robert Redfield, Institute of Human Virology

    1:00 John Bartlett, Johns Hopkins University School of Medicine

    Ten Draconian Changes in HIV Care for 2013 B101

    1:20 Bruce Gilliam, Institute of Human Virology

    AIDSRelief: Lessons Learned B102

    1:40 Lottie Hachaambwa, Maryland Global Initiatives Corporation (MGIC) Zambia

    The Zambian Medical Education Program B103

    2:00 Myron Cohen, University of North Carolina

    Integrated Prevention of HIV: The Way Forward B104

    2:20 Break – 20 minutes

    2:40 Jerome Kim, US Military HIV Research Program

    RV144: Progress in correlates, breakthrough viruses, and clinical development B105

    3:00 James Rooney, Gilead

    New Nucleotides for the treatment of HIV infection B106

    3:20 Pablo Tebas, University of Pennsylvania

    Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects B107

    3:40 Paolo Rossi, Children Hospital “Bambino Gesu”

    Therapeutic DNA vaccination in HIV-infected children and adolescents: 96 weeks data from the PEDVAC Trial B108

    4:00 Maja Sommerfelt, Bionor Immuno

    Vacc-4x and Vacc-C5: Two peptide-based therapeutic HIV vaccine candidates B109

    4:20 Anuoluwapo Osinusi, CRMP, SAIC-Frederick Inc/NIAID, NIH

    Treatment for HCV in HIV Coinfected subjects: A new era of hope? B110

    5:00 Clinical Short Talks from Selected Abstracts, Grand Ballroom V

    Ignace Gashongore, Institute of Human Virology, Zambia

    Genotypic resistance patterns in patients failing first line art regimen in Zambia B111

    Nephthalie Mesidor, Institute of Human Virology Haiti

    An Evaluation of Distance and its Impact on Long-term Follow up Outcomes in a Rural HIV Clinic in Northern Haiti B112

    Barbara Bastien, Institute of Human Virology Haiti

    Why Are They Dying? Describing Factors Associated With Mortality Among ART Patients in Rural Haiti B113

    Michael Mukiibi, Institute of Human Virology Nigeria

    Proficiency Testing As a Quality Assessment Methodology in Acid Fast Bacilli Microscopy: The Experience of AIDSRelief B114

    Anthea Nwandu, Institute of Human Virology Nigeria

    Effects of a Maternal Infant HIV Care Clinic for HIV-infected mothers and exposed infants on follow up postnatal HIV testing and care in Southeastern Nigeria: A retrospective review B115

    Emmanuel Mugisa, Institute of Human Virology Uganda

    Implementation of Cervical cancer screening services at 9 IHV/PEPFAR supported ART clinics in Uganda; Successes and challenges B116

    6:30 Welcome Reception, Grand Foyer West

    Back to Top | Article Outline

    Monday, October 15, 2012

    Grand Ballroom V

    Track C

    HIV Pathogenesis

    Chairs: William Hall, University College Dublin and Luigi Buonaguro, Università Vita-Salute San Raffaele

    9:00 Joel Blankson, Johns Hopkins University

    Viral Reservoirs in Elite Suppressors; a Possible Model for a Functional Cure? C101

    9:20 Mathias Lichterfeld, Massachusetts General Hospital

    Cell-intrinsic HIV-1 immune defense in elite controllers C102

    9:40 Eric Verdin, University of California Francisco

    Identification, purification and characterization of latently-infected cells using novel fluorescent HIV viruses C103

    10:00 Leonid Margolis, National Institutes of Health

    Flow virometry: A nanotechnology for analysis of individual viral particles C104

    10:20 Break - 20 minutes

    10:40 Jim Arthos, National Institutes of Health

    Glycosylation in HIV Transmission C105

    11:00 George Shaw, University of Pennsylvania

    Distinguishing Features of Transmitted/Founder HIV-1 C106

    11:20 Mirko Paiardini, Emory

    Preservation of Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with IL-21 C107

    11:40 Ashley Haase, University of Minnesota

    Impact of a live attenuated SIV vaccine on early events in transmission C108

    12:00 Lunch

    Track D

    Structural Biology of Immunity and Vaccines

    Chairs: Guido Poli, Ospedale San Raffaele and Eric Sundberg, Institute of Human Virology

    2:00 Ellis Reinherz, Dana Farber Harvard

    The cardinal rule of antibody - and CTL-eliciting vaccine design: specificity in a biological context D101

    2:20 Sriram Subramaniam, National Institutes of Health

    Molecular structures of trimeric HIV-1 and SIV envelope glycoproteins D102

    2:40 Kelly Lee, University of Washington

    Structure, dynamics and antigenicity in HIV Env: A bridge from structure to phenotype and function D103

    3:00 Marzena Pazgier, Institute of Human Virology

    Structural definition of new transitional epitopes exposed by CD4 binding to the HIV-1 D104

    3:20 William Schief, IAVI and The Scripps Research Institute

    Reverse engineering HIV vaccines D105

    3:40 Break – 20 minutes

    4:00 Pamela Bjorkman, California Institute of Technology

    Overcoming HIV Pathways for Escape using Rationally-Designed Anti-HIV Antibodies D106

    4:40 Peter Kwong, National Institute of Allergy and Infectious Diseases

    Effective CD4-binding-site antibodies: Atomic-level structures and ontogenies D107

    5:00 Lai-Xi Wang, Institute of Human Virology

    Synthetic HIV-1 Glycopeptides Enable Characterization of Fine Epitopes of Broadly Neutralizing Antibody PG9 D108

    5:20 Peter Sun, National Institutes of Health

    The role of Siglec in HIV infection D109

    6:30 Short-Talks from Selected Abstracts, Refreshments, Grand Ballroom V

    Chairs: Maria Salvato and Yutaka Tagaya, Institute of Human Virology

    Haishan Li, Institute of Human Virology

    Mechanisms for HIV envelope-induced CD4 T cell death: implications for novel therapeutic strategy against HIV disease ST101

    Priyamvada Acharya, Vaccine Research Center, NIAID

    Structural Basis for Broad and Potent HIV-1 neutralization by CD4-mimetic miniproteins ST102

    Shibo Jiang, Shanghai Medical College, Fudan University, China,

    Lindsley F. Kimball Research Institute, New York Blood Center

    HIV-1 variants with mutations in the gp41 pocket region are resistant to HIV fusion inhibitors with pocket-binding domain, but sensitive to T20 ST103

    Francesca Caccuri, Medical School, University of Brescia

    HIV-1 matrix protein p17 is a pro-angiogenic chemokine acting via CXCR1/CXCR2-mediated activation of Akt-dependent ERK signaling ST104

    Anne Van den Broeke, Unit of Animal Genomics, Université de Liège (ULG), Université Libre de Bruxelles (ULB), Institut Jules Bordet

    Deep sequencing reveals abundant Pol III retroviral microRNA cluster in Bovine Leukemia Virus-induced leukemia ST105

    Michael McGrath, UCSF Department of Laboratory Medicine

    Macrophage targeted therapy for AIDS: Regulation of monocyte differentiation with PA300, a novel oral form of MGBG that reverses CNS and myocardial disease in a SIV model ST106

    Yeshitila Friew, Institute of Human Virology

    Suitability and Approval of HIV Rapid Test Kits after Arrival In-Country ST107

    Ira Berkower, Center for Biologics, FDA

    Live, attenudated rubella viral vectors expressing SIV and HIV vaccine antigens grow well in vivo and are immunogenic ST108

    Rajnish Kumar, NYU/VA Medical Center

    Antigenic specificity and neutralizing activity of antibody responses elicited by different gp120/mAb immune complex vaccines ST109

    Joachim Denner, Robert Koch Institute

    Function of the immunosuppressive domain of the transmembrane envelope protein gp41 in HIV induced immunosuppression ST110

    Mohammad A. Rai, Weatherall Institute of Molecular Medicine

    Immune selection and vpu variability in a unique narrow source HIV-Positive village cohort ST111

    Enass Abdel-Hameed, University of Cincinnati Medical Center

    Expressions of methyltransferase enzymes correlate with FOXP3 methylation in the colon mucosa of HIV-1 infected patients ST112

    Bassam Badran, Free University of Brussels

    Human CD4+CD25+CD127low Regulatory T cells: Transcriptional profile, microRNA signature and regulation of FOXP3 and CTLA-4 expression by differentially expressed microRNAs ST113

    Sayed Abdelwahab, Minia University

    IL28B SNP does not predict the outcome of Hepatitis C Virus-specific cellular immune response ST114

    Back to Top | Article Outline

    Tuesday, October 16, 2012

    Grand Ballroom V

    Track E/F

    Preventive HIV Vaccine

    Chairs: Reinhard Kurth, Robert-Koch Institute and Nina Russell, The Gates Foundation

    8:30 Nelson Michael, U.S. Military HIV Research Program,

    Advances in Preventive HIV Vaccine Development E101

    8:50 David Montefiori, Duke University Medical Center

    Magnitude, Breadth and Duration of HIV-1 Vaccine-Elicited Neutralizing Antibody Responses E102

    9:10 Georgia Tomaras, Duke University Medical Center

    HIV-1 Vaccine Elicited IgA and IgG Antibody Specificities E103

    9:30 Susan Zolla-Pazner, New York University

    Identification of Three Distinct Epitope Regions in the V2 Portion of gp120 E104

    9:50 Break - 20 minutes

    10:10 Abraham Pinter, New Jersey Medical School

    Exploring the role of conformational heterogeneity in the V1/V2 domain of HIV-1 gp120 on the immunological properties of Env immunogens E105

    10:30 Yongjun Guan, Institute of Human Virology

    Diversity of Antibody Germline Gene and HIV-1 Infection: Implication for HIV-1 Vaccine E106

    10:50 James Crowe, Vanderbilt

    Complexity of human naïve B cell repertoires: The starting point for induction of neutralizing antibodies E107

    11:10 Barton Haynes, Duke University

    Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design E108

    11:30 Anthony Fauci, National Institutes of Health

    Martin Delaney Memorial Lecture Sponsored by Gilead Sciences Ending the HIV/AIDS Pandemic: Research and Implementation E109

    12:00 Lunch

    1:30 Genoveffa Franchini, National Institutes of Health

    Antibodies to the gp120 envelope protein in protection of macaques from SIVmac251 acquisition E110

    1:50 John Moore, Weill Medical College of Cornell University

    Vaccine-microbicide combination studies in a rhesus macaque vaginal transmission model E111

    2:10 George Pavlakis, National Cancer Institute

    DNA and combination vaccines for a durable and effective response E112

    2:30 Tetsuro Matano, The University of Tokyo

    SIV control by vaccine-based Gag/Vif-specific CTL induction E113

    2:50 Steven Reed, Infectious Disease Research Institute

    Rational Design and Clinical Development of New Adjuvants E114

    3:10 Break – 20 minutes

    4:00 Lifetime Achievement Awards – Honorary Talks

    Robert Redfield, IHV, speaking on behalf of John Bartlett

    Lishan Su, UNC, speaking on behalf of Yi Zeng

    Jay Berzofsky, NIH, speaking on behalf of Tom Waldmann

    6:30 Gala Reception, Grand Foyer West

    7:30 Gala Awards Banquet, Grand Ballroom I and II

    Back to Top | Article Outline

    Wednesday, October 17

    Grand Ballroom V

    Track G

    Viral Oncology

    Chairs: Robert Gallo, Institute of Human Virology and Kevin Cullen, Greenebaum Cancer Center

    9:00 Harold Varmus, National Cancer Institute

    Howard Temin Memorial Lecture Sponsored by Profectus Biosciences

    9:20 Micah Luftig, Duke University

    Studies at the oncogenic virus/host interface: Dynamic regulation of Epstein-Barr virus-mediated B cell immortalization G101

    9:40 Lou Laimins, Northwestern University

    Activation of differentiation-dependent human papillomavirus life cycle through the ATM DNA damage pathway G102

    10:00 Doug Lowy, National Institutes of Health

    The mechanisms by which HPV vaccines induce protection against HPV-associated cancers G103

    10:20 Franco Buonaguro, Istituto Nazionale Tumori “Fond. G. Pascale”

    Molecular Signatures in Human Liver Cancer G104

    10:40 Break - 20 minutes

    11:00 Patrizia Farci, National Institutes of Health

    Profibrogenic Chemokines and Viral Evolution Predict Rapid Progression of Hepatitis C to Cirrhosis G105

    11:20 Masao Matsuoka, Institute for Virus Research, Kyoto University

    Pathogenic roles of HTLV-1 bZIP factor gene G106

    11:40 Arnaldo Caruso, University of Brescia

    HIV-1 p17 variants induces Akt phosphorylation and B cell growth G107

    12:00 Adjourn

    © 2013 Lippincott Williams & Wilkins, Inc.